W ith the exception of surgical interventions, treatment options for intracranial aneurysms are limited, thus greater insight into molecular mechanisms that control formation and rupture of intracranial aneurysms may lead to new treatment options. The wall of human intracranial aneurysms is rich in inflammatory cells and molecules.
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Methods
Experimental Animals
Studies were performed in adult (11±1 months) wild-type (WT) and Mas receptor-deficient (Mas KO) mice. The mice were bred on the C57BL6 background, as described previously. 15 All experimental protocols and procedures conform to the National Institute of Health guidelines and were approved by the Institutional Animal Care and Use Committee of the University of Iowa.
Aneurysms were induced in mice according to published methods, 16 using the combination of stereotactic injection of elastase in the basal cistern and hypertension induced by systemic administration of Ang II (or Ang II+Ang 1-7) using osmotic minipumps. Systolic blood pressure was measured using the tail cuff method. Animals were monitored daily and euthanized immediately if signs of neurological deficit were apparent or after 3 weeks. Cerebral arteries isolated from mice with aneurysms and shams were used for gene expression analysis by real-time quantitative polymerase chain reaction.
Human Intracranial Aneurysms
Studies were approved by the University of Iowa Internal Review Board. Samples of intracranial aneurysms and arteries were collected from patients who underwent microsurgical clipping. The expression of Mas receptor was examined using immunostaining.
Drugs
Ang 1-7 and Ang II were obtained from Bachem (Torrance, CA). All other reagents were obtained from Sigma (St Louis, MO).
Statistical Analysis
Analysis was performed using Prism 6 (Graphpad, La Jolla, CA). Categorical data (incidence of aneurysms and subarachnoid hemorrhage) were compared between mice treated with Ang II or Ang II+Ang 1-7 using 1-tailed Fisher exact test. Survival was analyzed with log-rank (Mantel-Cox) test. Gene expression in cerebral arteries from sham, Ang II, and Ang II+Ang 1-7 WT mice was analyzed using 1-way ANOVA followed by Tukey post hoc test. Gene expression in Mas KO mice treated with Ang II or Ang II+Ang 1-7 was analyzed with unpaired t test. A P value <0.05 was considered significant. Additional information can be found in the online-only Data Supplement.
Results
Effect of Ang 1-7 in the Formation and Rupture of Intracranial Aneurysms
Systolic pressure increased significantly after intracranial stereotactic injection of elastase and implantation of osmotic pumps containing Ang II (mean±SE, 148±5 mm Hg) or Ang II+Ang 1-7 (144±5 mm Hg; P<0.05; Figure 1A ) versus baseline. Ang II-induced hypertension was not attenuated by Ang 1-7 after 1, 2, or 3 weeks of treatment.
When compared with control mice (Figure 2A ), ≥80% of hypertensive mice that received an intracranial injection of elastase displayed evidence of fusiform and/or saccular intracranial aneurysms during necropsy ( Figure 2B ). Most aneurysms were saccular or a mix of saccular and fusiform aneurysms; <20% were fusiform aneurysms. In some mice, ruptured aneurysms were identified near areas of subarachnoid hemorrhage ( Figure 2B , left).
Mortality was higher in mice treated with Ang II (64% [18/28] ) than in mice treated with Ang II+Ang 1-7 (36% [9/25] ; P<0.05; Figure 1B Figure 1D ).
Formation and Rupture of Intracranial Aneurysms in Mas KO Mice
Similar studies were performed in Mas KO mice. Increase in systolic pressure was similar in Mas KO mice after intracranial stereotactic injection of elastase and infusion of Ang II or Ang II+Ang 1-7 (136±4 versus 136±8 mm Hg), respectively ( Figure 3A) . Mortality of Mas KO mice treated with elastase and Ang II was lower than in WT mice under the same treatment (P<0.05). In Mas KO mice, Ang 1-7 did not reduce mortality ( Figure 3B ). Ang 1-7 did not attenuate formation of aneurysms in Mas KO mice treated with Ang II (84% [16/19] Ang II versus 100% [14/14] Ang II+Ang 1-7-treated mice; Figure 3C ). Ang 1-7 did not reduce incidence of subarachnoid hemorrhage: 53% (10/19) versus 64% (9/14) in Mas KO mice treated with Ang II or Ang II+Ang 1-7, respectively (P>0.05; Figure 3D ).
Expression of Genes Involved in Vascular Injury
The expression of several genes involved in vascular inflammation, oxidative stress, and extracellular matrix remodeling was examined in cerebral arteries. In WT mice, intracranial injection of elastase and infusion of Ang II increased the expression of the proinflammatory cytokines tumor necrosis factor-α, integrin alpha M (Itgam; a marker of macrophage infiltration), and the proinflammatory enzyme microsomal prostaglandin E2 synthase-1 (P<0.05; Figure 4 ). Elastase+Ang II also increased the expression of Nox2, catalase, and the wound repair factor, hepatocyte growth factor. Coinfusion of Ang 1-7 did not attenuate the expression of inflammation mediators/markers or enzymes associated with oxidative stress in cerebral arteries, but notably increased the expression of cyclooxygenase-2. Elastase+Ang II increased the expression of matrix metalloproteinase (MMP)-9, MMP-2, and tissue inhibitor of metalloproteinases-1. Coinfusion of Ang 1-7 markedly attenuated the increase in MMP-9 in cerebral arteries ( Figure 4) .
In Mas KO, combination of intracranial injection of elastase and Ang II also increased the expression of molecules associated with inflammation, oxidative stress, and vascular remodeling. In these mice, coinfusion of Ang 1-7 did not alter the changes in gene expression induced by elastase+Ang II ( Figure 5 ). In Mas KO mice, coinfusion of Ang 1-7 did not attenuate the increased expression of MMP-9 or the increased expression of cyclooxygenase-2 induced by elastase+Ang II.
Expression of Mas Receptor in Human Aneurysms
Mas receptor expression was demonstrated in media and intima of control human arteries (meningeal and superficial temporal arteries). Immunostaining for Mas was also positive in sections of unruptured and ruptured human intracranial aneurysms ( Figure 6 ).
Discussion
In the current study, we replicated a model of intracranial aneurysms in mice. 16 As first demonstrated by Nuki et al, 16 cerebral aneurysms are produced in ≈80% of mice treated with Ang II and intracranial injections of elastase. Using this model, we observed that Ang 1-7 decreased mortality and frequency of rupture of intracranial aneurysms in mice. Moreover, protective effects of Ang 1-7 on aneurysm rupture were absent in Mas KO. Finally, Ang 1-7 decreased Ang II-induced increases in the expression of MMP-9 in cerebral arteries.
Ang 1-7 has several protective effects in models of stroke.
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Ang 1-7 decreased oxidative stress, apoptosis, and autophagosome formation in spontaneously hypertensive rats. 18, 19 Ang 1-7 decreased infarct size and neurological deficit after middle cerebral artery occlusion in rats. [20] [21] [22] Moreover, Ang 1-7 increased survival of stroke-prone spontaneously hypertensive rats. 23 In our study, we focused on effects of Ang 1-7 in cerebral arteries in a model of intracranial aneurysms.
Because Ang 1-7 counteracts some of the deleterious effects of Ang II, [6] [7] [8] [9] we anticipated that Ang 1-7 might reduce susceptibility to cerebral aneurysms in this model. However, it was not clear whether Ang 1-7 would be sufficiently potent, especially against key mechanisms, to have a detectable effect on aneurysms. A broader implication of our findings is that hypertension, which is often associated with activation of the renin/angiotensin system, is a major risk factor for rupture of aneurysms, and Ang 1-7 may be effective in protection against rupture of aneurysms.
Ang 1-7 attenuated aneurysm rupture but did not reduce the hypertensive effect of Ang II in our study. Antihypertensive effects of Ang 1-7 are not clear. Although Ang 1-7 decreased blood pressure in spontaneously hypertensive rat, 24, 25 it failed to reduce blood pressure in other models of hypertension. 9, 26, 27 Our results agree with studies in which Ang 1-7 did not attenuate the increase in systolic blood pressure induced by Ang II or deoxycorticosterone acetate-salt. 9, 26, 27 Similarly, delivery of Ang 1-7 to the cerebral ventricles of spontaneously hypertensive rat Thus, attenuation of aneurysm rupture by Ang 1-7 is not the result of an antihypertensive action of Ang 1-7. Inflammation seems to play an important role in rupture of intracranial aneurysms. Proinflammatory enzymes, such as cyclooxygenase-2 and microsomal prostaglandin E2 synthase-1, are increased in the wall of ruptured cerebral aneurysms in humans. 1 Infiltration of leukocytes into the cerebral aneurysmal wall has also been found in humans. 2 Macrophage depletion, or decreased vascular macrophage infiltration in cerebral arteries from monocyte chemoattractant protein-1-deficient mice, is associated with decreased aneurysm formation and rupture in mice. 3, 28 We found that Ang II increased the expression of tumor necrosis factor-α and microsomal prostaglandin E2 synthase-1 in cerebral arteries and increased macrophage infiltration assessed by the specific macrophage marker integrin alpha M.
Ang 1-7 has multiple beneficial actions in blood vessels.
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Ang 1-7 dilates cerebral arteries 29 and seems to attenuate neurological damage in stroke. [20] [21] [22] Ang 1-7 also increases survival and decreases the number of subcortical hemorrhages in stroke-prone hypertensive rats. 23 Part of the protective effect of Ang 1-7 in stroke seems to be related to its modulatory effects on nuclear factor-κB 20 and inflammation. 22, 23 Therefore, it was of interest that Ang 1-7 decreased aneurysm rupture and mortality without decreasing Ang II-induced infiltration of macrophages or overexpression of tumor necrosis factor-α and microsomal prostaglandin E2 synthase-1 in cerebral arteries.
Ang 1-7 increased cyclooxygenase-2 expression in cerebral arteries. Although cyclooxygenase-2 is generally associated with inflammatory responses, it is also responsible for the synthesis of prostacyclin, which is vasoprotective. 30 Protective effects of Ang 1-7 in the heart are attenuated by the cyclooxygenase inhibitor, indomethacin. 31 Thus, although Ang 1-7 did not seem to attenuate inflammation in our study, it is possible that some of the protective effects of Ang 1-7 may be mediated by increased synthesis of prostacyclin through the cyclooxygenase-2 pathway.
Expression and activation of MMPs play a critical role in aneurysm rupture. Increased expression of MMP-2 and MMP-9 is seen in patients with ruptured cerebral aneurysms. 32 Increased expression of MMP-2 and MMP-9 is associated with progression of cerebral aneurysms in rats. 33 Pharmacological inhibition of MMPs decreases aneurysm rupture in mice. 34 We found that Ang 1-7 attenuated Ang II-induced increase in the expression of MMP-9. Pathways by which Ang 1-7 or the Mas receptor regulate MMP expression are not known.
Ang 1-7 did not attenuate effects of intracranial injection of elastase and Ang II in Mas KO. Increased expression of cyclooxygenase-2 by Ang 1-7 was not observed in Mas KO mice. Moreover, in contrast to findings in WT mice, Ang 1-7 tended to increase the levels of MMP-2 and MMP-9 in cerebral arteries of Mas KO mice with intracranial aneurysms. Because Ang 1-7 is a weak agonist of Ang II receptors, 35 we speculate that, in the absence of Mas receptors, Ang 1-7 may activate angiotensin type 1 receptors for Ang II and may induce further vascular damage. Our studies in Mas KO mice indicate that mice deficient in the receptor Mas had a lower mortality. This finding is puzzling because most literature suggests that the activation of Mas receptors generally plays a protective role in disease, thus its deletion would be expected to exacerbate vascular damage. However, there are exceptions to this generalization because Mas activation is associated with aggravation of renal 36 and cardiac 37 disease and liver steatosis. 38 In these experimental models, genetic deletion of Mas is associated with better outcomes. [36] [37] [38] Little is known about intracellular signaling pathways activated by Mas receptors or regulation of other receptors, such as angiotensin type 1 by Mas. Thus, we speculate that when Ang 1-7 levels are low, Mas receptors may not signal or may not regulate the activation of pathways, such as those activated by angiotensin type 1 receptors. In contrast, in conditions in which Ang 1-7 levels increase, Mas is activated and can physiologically antagonize other pathways, including the Ang II pathway.
Perspective
We demonstrated that the Mas receptor is expressed in the wall of human arteries and intracranial aneurysms. In addition, the infusion of Ang 1-7 attenuated aneurysm rupture and mortality in a mouse model of intracranial aneurysms. Ang 1-7 did not decrease the expression of markers of inflammation but regulated the expression of MMP-9 and cyclooxygenase-2. In conclusion, this study implies a potential novel therapeutic strategy for medical management of intracranial aneurysms. Additional studies may explore pharmacological strategies to modulate Ang 1-7 signaling in human intracranial aneurysms via agonists of the Mas receptor.
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